Lipfendra is the first once-daily oral PCSK9 inhibitor approved in the U.S. It lowered LDL cholesterol substantially in trials—but it is not yet a proven replacement for an outcomes-focused treatment plan.
Merck's Lipfendra (enlicitide) was approved on July 16, 2026 as the first once-daily oral medicine in the PCSK9 inhibitor class. For people who need more LDL-cholesterol lowering than diet, exercise, and statins can provide, the convenience of a pill rather than an injection could be consequential.
PCSK9 is a protein that affects how many LDL receptors the liver has available to clear LDL cholesterol from the bloodstream. Blocking PCSK9 allows more receptors to remain active, helping the liver remove more LDL.
Until Lipfendra, PCSK9-targeting therapies were administered by injection. Enlicitide is a macrocyclic peptide that blocks the interaction between PCSK9 and LDL receptors in a tablet form.
In the CORALreef Lipids and CORALreef HeFH trials, Lipfendra reduced LDL cholesterol by a placebo-adjusted 56% and 59%, respectively, at week 24. Those are substantial biomarker results.
The essential caveat: lower LDL is strongly associated with lower cardiovascular risk across many treatments, but Lipfendra has not yet independently demonstrated that it prevents heart attacks or strokes. It should be viewed within the specific FDA indication and a clinician-led risk-reduction plan, not as a guarantee of an outcome.
Lipfendra is indicated as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It is not a do-it-yourself response to a single high cholesterol result. A clinician will consider LDL level, family history, existing cardiovascular disease, other medicines, liver and kidney health, and whether statins or other options have been tried.
Home blood-pressure readings can be useful data for cardiovascular visits. They do not measure cholesterol and cannot tell you whether Lipfendra is appropriate. We may earn a commission from the following link at no extra cost to you.
Lipfendra makes oral PCSK9 inhibition a real option for qualifying adults, with striking LDL reductions in its trials. The heart-attack and stroke outcome question remains open, so treatment decisions should stay anchored to your individual cardiovascular risk and clinician guidance.